Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anisha B Patel

Showing results (81-90 of 87) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 87 results.
Cancer Prevention Research (Philadelphia, Pa.)|October 13, 2022
Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast CancerParijatham S Thomas, Anisha B Patel, J Jack Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2021
Poziotinib for Patients With <i>HER2</i> Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II TrialYasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, et al.
Frontiers in Immunology|September 9, 2024
Toxicity in the era of immune checkpoint inhibitor therapySynat Keam, Naimah Turner, Fernanda G Kugeratski, et al.
Cancer|November 1, 2021
Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefitAnisha B Patel, Sahira Farooq, Macartney Welborn, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 22, 2024
Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literatureChristopher Iriarte, Jennifer E Yeh, Allireza Alloo, et al.
Cancer|July 6, 2022
Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort studyVinod Ravi, Aparna Subramaniam, Jing Zheng, et al.
Journal for Immunotherapy of Cancer|April 10, 2024
Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapySteven T Chen, Yevgeniy R Semenov, Allireza Alloo, et al.
Pageof 9

Showing results (81-90 of 87) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 87 results.
Cancer Prevention Research (Philadelphia, Pa.)|October 13, 2022
Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast CancerParijatham S Thomas, Anisha B Patel, J Jack Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 22, 2021
Poziotinib for Patients With <i>HER2</i> Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II TrialYasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, et al.
Frontiers in Immunology|September 9, 2024
Toxicity in the era of immune checkpoint inhibitor therapySynat Keam, Naimah Turner, Fernanda G Kugeratski, et al.
Cancer|November 1, 2021
Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefitAnisha B Patel, Sahira Farooq, Macartney Welborn, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 22, 2024
Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literatureChristopher Iriarte, Jennifer E Yeh, Allireza Alloo, et al.
Cancer|July 6, 2022
Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort studyVinod Ravi, Aparna Subramaniam, Jing Zheng, et al.
Journal for Immunotherapy of Cancer|April 10, 2024
Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapySteven T Chen, Yevgeniy R Semenov, Allireza Alloo, et al.
Pageof 9